We came across a bullish thesis on Bristol-Myers Squibb Company (BMY) on Substack by Magnus Ofstad. In this article, we will ...

William Blair upped their Q2 2025 earnings estimates for Bristol-Myers Squibb in a note issued to investors on Tuesday, March ...

Abecma is being jointly developed and commercialized in the U.S. as part of a co-development, co-promotion, and profit share ...

Bristol Myers Squibb Co. closed 6.82% below its 52-week high of $63.33, which the company reached on March 11th.

Bristol-Myers Squibb acquires 2seventy bio for $286M, marking the end of a once-promising biotech. Check out if this is a ...

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Ascend Wellness Holdings LLC (AAWH – Research ...

Bristol Myers Squibb will acquire 2seventy bio for about $286 million in cash, sending the cancer cell therapy maker's shares ...

Bristol-Myers Squibb was founded in 1858 and has grown to be one of today's leading global pharmaceutical companies. For over 150 years, Bristol-Myers Squibb (BMS) has been committed to "discover ...

Shares of 2seventy bio took flight Tuesday after the biotechnology company agreed to be acquired by partner Bristol Myers Squibb. Bristol Myers is paying $5 a share in cash for 2seventy, a 79% premium ...

Bristol Myers Squibb is acquiring 2seventy bio, a deal that gives the pharmaceutical giant full control over the partnered cancer cell therapy Abecma as that product faces headwinds in a ...

March 11 (Reuters) - Bristol Myers Squibb (BMY.N), opens new tab will acquire 2seventy bio (TSVT.O), opens new tab for about $286 million in cash, sending the cancer cell therapy maker's shares up ...